Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
30
04
2021
accepted:
30
08
2021
revised:
24
08
2021
pubmed:
10
9
2021
medline:
2
4
2022
entrez:
9
9
2021
Statut:
ppublish
Résumé
p53 immunohistochemistry has long been proposed for the separation of benign from malignant mesothelial proliferations, with the older literature suggesting that any degree of positivity supported a diagnosis of mesothelioma. However, using modern immunohistochemistry platforms in other organ systems, notably gynecologic tumors, it has become clear that p53 staining can represent wild-type protein, and only specific staining patterns (absent, overexpression, or cytoplasmic expression) are indicative of a TP53 mutation. We applied these principles to two tissue microarrays containing 94 mesotheliomas and 66 reactive mesothelial proliferations. Seven/65 (11%) epithelioid mesotheliomas showed aberrant staining (four absent and three overexpression patterns) as did 5/29 (17%) of sarcomatoid mesotheliomas (all overexpression patterns). We sequenced the TP53 gene (exons 2-11) in five of the epithelioid and three of the sarcomatoid cases with aberrant staining as well as 12 epithelioid and eight sarcomatoid mesotheliomas with wild-type staining. All three sarcomatoid cases with aberrant staining showed mutated TP53, as did three of the epithelioid cases; in two of the epithelioid cases no mutation was detected, most likely because of large deletions not detected by this assay. In contrast, none of the 20 mesotheliomas with wild-type staining contained mutated TP53. We conclude that absent or overexpression p53 staining patterns can be used as a marker of a malignant vs. a benign mesothelial proliferation. The sensitivity of p53 staining by itself is low, but here addition of p53 to BAP1/MTAP staining increased sensitivity from 72 to 81% for epithelioid and 38 to 50% for sarcomatoid mesotheliomas.
Identifiants
pubmed: 34497363
doi: 10.1038/s41379-021-00920-9
pii: S0893-3952(22)00353-2
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-81Informations de copyright
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Singh, N. et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J. Pathol. 250, 336–345 (2020).
doi: 10.1002/path.5375
Köbel, M. et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int. J. Gynecol. Pathol. 35, 430–441 (2016).
doi: 10.1097/PGP.0000000000000274
Köbel, M. et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J. Pathol. Clin. Res. 2, 247–258 (2016).
doi: 10.1002/cjp2.53
Hasteh, F., Lin, G. Y., Weidner, N. & Michael, C. W. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 118, 90–96 (2010).
doi: 10.1002/cncy.20071
Mangano, W. E., Cagle, P. T., Churg, A., Vollmer, R. T. & Roggli, V. L. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am. J. Clin. Pathol. 110, 191–199 (1998).
doi: 10.1093/ajcp/110.2.191
Churg, A. & Galateau-Salle, F. The separation of benign and malignant mesothelial proliferations. Arch. Pathol. Lab. Med. 136, 1217–1226 (2012).
doi: 10.5858/arpa.2012-0112-RA
Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565 (2018).
doi: 10.1158/2159-8290.CD-18-0804
Markowitz, P. et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat. Res. Commun. 25, 100232 (2020).
doi: 10.1016/j.ctarc.2020.100232
Pagano, M. et al. Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES Study. Cancers 12, https://doi.org/10.3390/cancers12102948 (2020).
Campanella, N. C. et al. Mutational profiling of driver tumor suppressor and oncogenic genes in Brazilian malignant pleural mesotheliomas. Pathobiology 87, 208–216 (2020).
doi: 10.1159/000507373
Yang, H., Xu, D., Schmid, R. A. & Peng, R.-W. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther. Adv. Med. Oncol. 12, 1758835920971421 (2020).
pubmed: 33240401
pmcid: 7672749
Hung, Y. P. et al. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod. Pathol. 33, 2269–2279 (2020).
doi: 10.1038/s41379-020-0588-y
Quetel, L. et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol. Oncol. 14, 1207–1223 (2020).
doi: 10.1002/1878-0261.12651
King, J., Thatcher, N., Pickering, C. & Hasleton, P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49, 561–568 (2006).
doi: 10.1111/j.1365-2559.2006.02442.x
Salisbury, T. & Churg, A. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations. Virchows Arch. https://doi.org/10.1007/s00428-021-03077-7 (2021).
Köbel, M. et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 222, 191–198 (2010).
doi: 10.1002/path.2744
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
doi: 10.1093/nar/gkx1153
Tessier-Cloutier, B. et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod. Pathol. 33, 1595–1605 (2020).
doi: 10.1038/s41379-020-0524-1
Attanoos, R. L., Griffin, A. & Gibbs, A. R. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43, 231–238 (2003).
doi: 10.1046/j.1365-2559.2003.01686.x
Roberts, F., Harper, C. M., Downie, I. & Burnett, R. A. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am. J. Clin. Pathol. 116, 253–262 (2001).
doi: 10.1309/XL6K-8E62-9FLD-V8Q8
Cury, P. M., Butcher, D. N., Corrin, B. & Nicholson, A. G. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 189, 251–257 (1999).
doi: 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F
Kafiri, G. et al. p53 expression is common in malignant mesothelioma. Histopathology 21, 331–334 (1992).
doi: 10.1111/j.1365-2559.1992.tb00403.x
Mayall, F. G., Goddard, H. & Gibbs, A. R. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J. Pathol. 168, 377–381 (1992).
doi: 10.1002/path.1711680407
Ramael, M. et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol. 168, 371–375 (1992).
doi: 10.1002/path.1711680406
Cagle, P. T., Brown, R. W. & Lebovitz, R. M. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum. Pathol. 25, 443–448 (1994).
doi: 10.1016/0046-8177(94)90115-5
Esposito, V. et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res. 17, 733–736 (1997).
pubmed: 9066611
Churg, A. & Naso, J. R. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am. J. Surg. Pathol. 44, e100–e112 (2020).
doi: 10.1097/PAS.0000000000001565
Derakhshan, F., Ionescu, D., Cheung, S. & Churg, A. Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions. Arch. Pathol. Lab. Med. 144, 185–188 (2020).
doi: 10.5858/arpa.2019-0370-OA
Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016).
doi: 10.1038/ng.3520
Köbel, M. et al. Interpretation of p53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int. J. Gynecol. Pathol. 38(Suppl 1), S123–S131 (2019).
doi: 10.1097/PGP.0000000000000488
Mairinger, F. D. et al. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. Future Oncol. 10, 995–1005 (2014).
doi: 10.2217/fon.13.261